Based on in vitro data suggesting that recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) is capable of stimulating acute myeloid leukemia (AML) blast cells t o become more sensitive t o cell-cycle-specific drugs we conducted a phase 1/11 study in de novo AML patients (pts). rhGM-CSF (250 pg/m2/d, continuous intravenous infusion) was administered in 18 pts suffering from de novo AML in combination with standard induction chemotherapy (3 + 7 = daunorubicin 45 mg/m2 days 1 through 3, cytosine-arabinoside [Ara-C] 200 mg/m2 continuous infusion days 1 through 7). GM-CSF was started 48 or 24 hours before chemotherapy (prephase) in 14 pts. In four pts with high white blood cell counts (WBC) rhGM-CSF was started after chemotherapy-induced cell reduction (WBC < 30,000/mm3).
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leukemias deserves special cautions. First, in vitro studies have shown that GM-CSF stimulates growth and differentiation of malignant myeloid cells through specific recept o r~~~" ' and, in addition, may be produced by leukemic cells under certain condition^.^'.^^ More recently, in patients (pts)
suffering from myelodysplastic syndromes (MDS), growth stimulation of blast cells and transition to acute leukemia was ob~erved.'~ These experiences discouraged clinical studies in acute myeloid leukemia (AML) pts using GM-CSF as a growth factor. On the other hand, we and others were able to demonstrate that recombinant human GM-CSF (rhGM-CSF) recruits quiescent AML cells in vitro to become more sensitive to cell-cycle-specific drugs and apparently promotes drug-induced cell ki11.35"9 Significantly better recruitment was found in newly diagnosed versus relapsed AML pts.3' The aims of the present study were to demonstrate the in vivo effects of rhGM-CSF on cell-cycle kinetics of AML cells and to investigate whether rhGM-CSF is capable of shortening the time of chemotherapy-induced cytopenia in de novo AML pts. requiring packed red blood cell (RBC) transfusions was found in two pts. Seven pts had fever greater than 38°C. Pt 6 had a large perirectal abscess and septicemia (Klebsiella oxytoca). Hemorrhage (epistaxis, gum bleeding, petechiae, subcutaneous hematomas) was noted in seven pts with thrombocytopenia. In pt 3 (AML-FAB M3) hypofibrinogenemia (178 mgidL), low a-2-antiplasmin (65%), and increased D-dimer levels (12.500 ngimL) were found. Impaired liver function (SGPT 73 U/L, y-GT 135 UIL) was found in pt 6. Kidney function was normal in all pts. The historical control group consisted of 39 de novo AML pts (excluding pts with AML following myelodysplastic syndrome), achieving complete remission (CR) after one cycle of the same chemotherapy regimen (3 + 7 = daunorubicin 45 mgim' days 1 through 3, cytosine-arabinoside [Ara-C] continuous infusion days 1 through 7) but without rhGM-CSF. The distribution of FAB subtypes in the control group was: M1 (n = 8), M2 (n = 13), M3 (n = 3), M4 (n = 5), M5 (n = 8), M6 (n = 2). The historical controls were neither age nor sex matched.
The material used was provided by Behring Company (Marburg, Germany). The human GM-CSF gene was isolated from libraries made from HUT-102 mRNA and was inserted into and expressed in E coli. The purified protein had a specific activity of approximately 5 x lo7 colony forming units (CFU)/mg protein.
The final product was formulated as lyophilized powder and reconstituted in aqueous buffer before use.
Treatment included administration of E coli-derived rhGM-CSF in combination with a standard cytotoxic remission induction chemotherapy protocol (3 + 7) as depicted in Fig 1 (see also ref 41 ). RhGM-CSF at a dose of 250 p,g/mZ daily was administered by continuous intravenous (IV) infusion and was delivered by an autosyringe pump through a central venous access line, 48 hours before chemotherapy (prephase). rhGM-CSF, continuous infusion, was administered until the neutrophil count (segmented and banded) was greater than 500Imm' (after chemotherapy-induced aplasia) and was then changed to subcutaneous application (125 pgim' twice daily) for the following 3 days (pts 1 through 6). In pts 7 through 18, the treatment protocol was modified according to initial results. Prephase was shortened to 24 hours to minimize the risk of rhCM-CSF.
Treatmentprotocol and study design.
leukostasis. rhGM-CSF was stopped on day 8 and continued on day 14. Subcutaneous application of GM-CSF at the end of the regimen was omitted in pts 7 through 18.
Only pts with initial white blood cell counts (WBC) less than 30,000/mm3 were eligible for prephase, otherwise rhGM-CSF was started after chemotherapy-induced WBC reduction (below 30,000/ mm') ( Fig 1B) . Because of an increase of serum creatinine in pt 2, rhGM-CSF dosage was decreased to 125 p,Lgjmz beyond day 6 in this patient. XDays from the onset of chemotherapy; the second values (pts 2,7, and 8) represent days of the second cycle. tsegmented and banded. At neutrophil counts >500/mm3, IV administration of rhGM-CSF was stopped in all pts.
5Thirty-nine AML patients achieving CR after one cycle of the same chemotherapy regimen but without rhGM-CSF.
Remission induction chemotherapy (3 + 7) consisted of daunorubicin (Farmitalia Carlo-Erba, Freiburg, Germany), 45 mpim' daily (days 1, 2, and 3) and Ara-C (Upjohn, Puurs, Belgium), 200 mpim', by continuous IV infusion for 7 days (days 1 through 7). If CR was not achieved with one cycle of therapy, a second cycle of chemotherapy (reinduction) was administered, consisting of the same drugs as used in the first cycle (again in combination with rhGM-CSF). "Before" denotes prior rhGM-CSF administration, "after" denotes 48 hours (pts 1 through 6) or 24 hours (pts 8, 10, and 11) after rhGM-CSF ++All pts except pts 7 and 12 had required packed RBC transfusions before study entry (hemoglobin < 8 g/dL).
tThese pts were not eligible for prephase; the counts were taken immediately before onset of chemotherapy. rhGM-CSF was started after chemotherapy-induced leukocyte reduction to less than 30,000/mm3 (pt 7: day 4; pt 13: day 3; pts 9 and 12: day 2).
prephase.
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From Packed RBC transfusions were administered to maintain hemoglobin levels of more than 8 g/dL and random platelets were administered when the platelet counts had decreased to less than 20,000/mm3. For infection prophylaxis we used norfloxacin (2 X 400 mgid orally) and to prevent fungal infections, amphotericin B or nystatin were administered orally. An empiric broad spectrum antibiotic regimen was administered when systemic infection was suspected.
Clinical monitoring prior and during therapy included standard clinical and laboratory investigations. Differential counts were performed daily. Toxicity was assessed using World Health Organization (WHO) criteria:' BM aspirates and/or biopsies were taken before and after the GM-CSF prephase as well as on days 7, 14, 21, and 28 after the onset of chemotherapy. CR was defined according to Cancer and Leukemia Group B (CALGB) criteria. Short-term cultures of peripheral blood (PB) and BM cells were performed according to standard techniques:'." Karyotypes were established according to the International System of Human Cytogenetic Nomenclat~re.4~
The time to recovery of WBC, neutrophils, and platelets of the study pts achieving CR within one cycle was compared with historical controls (see above) using the Student's t-test (unpaired).
Cell-cycle analysis was performed using three independent methods including D N N RNA, DNA/BrdU, and DNAKi67 flow cytometry as described. Mononuclear cells (MNC) were isolated from heparinized PB samples by density gradient centrifugation. Cellular DNNRNA content was measured using acridine orange flow cytometry, as de~cribed.~"~' This method allows the discrimination of cells in the Go-, G$-, S-, and G,M-phases of the cell cycle. DNA synthesis was further investigated using bromodeoxyuridine (BrdU) incorporaClinical and laboratoly monitoring.
Statistical analysis.
Cell-cycle analysis by pow cytomeoy. tion into DNA-synthesizing cells. In brief, 1 x 106 cells were incubated with BrdU (final concentration 10 pgimL) for 1 hour at 37°C with 5% CO,. Cells were then washed and tixed in cold ethanol. After treatment with RNAase, DNA was partially denaturated with heat at 85°C for 10 minutes. Anti-BrdU antibody (IU 4, courtesy of Dr F. Dolbeare, Lawrence Livermore National Laboratory, Livermore, CA) and thereafter goat antimouse IgGfluorescein were added. Counterstaining for total DNA content was performed using propidium iodide (for details see Vanderlaan et aId8 and Dolbeare et ald9).
To determine the growth fraction, simultaneous flow cytometric measurement of Ki67 and cellular DNA content was performed (Ki67 is a proliferation-associated human nuclear antigen present in all cell-cycle phases except GT). Cells were stained for flow cytometric measurement of growth fraction and cell-cycle phases as described by Larsen et al."
All immunofluorescence measurements were performed using flow cytometry (fluorescence-activated cell sorter [FACS], BectonDickinson, Mountain View, CA) and analyzed using the available Becton-Dickinson software, including Consort 30, FACScan Research Software, Lysis, and Paint-a-Gate.
In 11 pts, in vitro proliferation of AML blast cell populations in response to GM-CSF was analyzed by means of thymidine-uptake experiments. 'H-thymidine uptake assay was performed using standard techniques. In brief, PB MNC (105/well) was incubated in the presence or absence of GM-CSF (100 U/mL) for 48 hours in RPMI medium supplemented with 10% fetal calf serum (FCS) at 37°C in 5% CO,. Thereafter, 1 $3 'H-thymidine (New England Nuclear, Boston, MA) was added. Eight hours later, cells were harvested and the incorporated radioactivity was counted in a liquid scintillation counter.
RESULTS
Fifteen of 18 pts (83.3%) achieved CR, 12 did so with one cycle. In three pts (2,7, and 8), CR was obtained after a second cycle (again in combination with rhGM-CSF). Two pts (5 and 6) died in aplasia because of invasive pulmonary aspergillosis. Pt 18 achieved no remission after two cycles of therapy. After a median observation period of 9 months, nine pts are still in continuous CR (CCR) (see Table 2 ). Pt 3, who achieved CR after one cycle, died during consolidation therapy (Klebsiellapneumoniae sepsis). Six pts have relapsed within 2.0 to 16.4 months.
Effect of GM-CSF on PB and BM cells during prephase.
From the day of admission until starting rhGM-CSF, no substantial increase of WBC was seen in any pt. Fourteen pts were eligible for rhGM-CSF administration 48 or 24 hours before chemotherapy (see Table 3 ). addition, by DNNRNA and DNA/Ki67 flow cytometry to assess the effects of rhGM-CSF on cell-cycle stages of Ah4L cells. A substantial increase in percent BrdU-positive cells was observed after the prephase in PB (seven of seven pts)
as well as in BM specimens (three of four pts) (see Table 5 ). The incorporation of 'H-thymidine into BP AML cells was studied (before administration of GM-CSF) in 11 pts (1 through 6, and 8, 10, 14, 17, and 18). An (1.2-to 17.0-fold) increase in thymidine uptake was observed in 7 of 11 pts (2, 3,4, 6, 10, 14, and 17). In pts 1,5,8, and 18, no substantial increase in thymidine uptake upon stimulation with GM-CSF in vitro was found. Figure 3 shows that the chemotherapy-induced decrease of peripheral WBC in the study pts was not delayed as compared with historical controls. Despite continuation of rhGM-CSF infusion, WBC decreased within 24 hours following the onset of chemotherapy in 11 pts. In three pts (11, 14, and 15) peripheral WBC increased until day 2 after onset of chemotherapy (due to elevation of neutrophils and blasts) and thereafter decreased.
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In pts 7, 9, 12, and 13 (initial WBC >30,000/mm3), rhGM-CSF administration was started after chemotherapyinduced WBC reduction (day 4 in pts 7 and 13, and on day 2 in pts 9 and 12). In none of them was rhGM-CSF found to elevate peripheral WBC or any leukocyte subset during chemotherapy.
Day-7 BM examination showed aplasia in 7 of 12 pts tested. In 5 of 12 pts, residual blasts were present despite BM hypoplasia. BM examination on day 14 evidenced aplasia in 17 of 18 pts (in pt 18, a small population of residual blast cells was found). Hematopoietic recovery. Administration of rhGM-CSF was found to shorten the duration of chemotherapyinduced aplasia compared with historical controls (n = 39). In particular, in the 12 pts achieving CR after one cycle a neutrophil count of at least 500/mm3 was reached on day 22.5 ? 3.4 (historical controls: 25.2 ? 3.7, P < .05).
After myeloid recovery (peripheral absolute neutrophil counts [ANC] > 500/mm3), rhGM-CSF was administered SC for another 3 days in three pts (pts 1, 3, and 4), producing a maximum leukocytosis (up to 27,900/mm3) at the end of rhGM-CSF application. Thereafter, WBC spon-
Response following chemotherapy.
rhGM-CSF Lv. taneously decreased to normal values within 1 to 6 days. In nine pts (9 through 17) rhGM-CSF administration was stopped on the day when peripheral ANC were at least 500/mm3 (without subsequent SC administration). In two pts (11 and 12) a delayed leukocytosis (5 and 7 days after the end of rhGM-CSF) was observed, most likely because of systemic infections.
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Chemotherapy
Maturing neutrophils were the dominant leukocyte population found in PB smears in all pts achieving CR, including myeloid precursors (promyelocytes + myelocytes + metamyelocytes up to 32%). After the end of rhGM-CSF administration, myeloid precursor cells disappeared spontaneously (a representative course of WBC and differential counts is depicted in Fig 4) . This transient increase of immature cells in PB corresponded with the BM morphology findings. On day-21 BM examination, in four of seven pts achieving CR after one cycle marked hypercellularity with increased myeloid: erythroid ratio and predominance of immature cells, in particular promyelocytes (up to 35%), was found (a representative follow-up of BM morphology is shown in Fig  5) . Day 28 BM smears showed maturation indicating complete remission (blast cells <5%; promyelocytes + myelocytes: 11.2% to 22% v segmented + banded 20.4% to 37%), CR was confirmed cytogenetically in all pts. BM eosinophilia was present in four pts (8% to 39.2% eosinophils). Platelet counts of more than 100,000/mm3 were reached on day 24.4 k 2.5 in the rhGM-CSF-treated pts versus day 24.4 f 4.7 in the historical controls (not significant). Effects on RBC counts and reticulocytes with respect to early recovery were not found in any pts (data not shown).
In pts 2, 7, and 8, who did not enter CR after one cycle (15.2% to 27% blasts on day-28 BM examination), only a slight increase of WBC was observed during the recovery period (Table 2) . CR was achieved in these three pts after a second cycle of treatment (same combination with rhGM-CSF, beginning between day 33 and 44 from the onset of the fist cycle). Myeloid recovery was characterized by a steep WBC increase with ANC greater than 500/mm3 on days 22 (pts 7 and 8) and 23 (pt 2) of the second cycle with differential count features analogous to the seven pts described above. Pt 18 presented with greater than 25% BM blasts on day 28 of the second cycle and was therefore classified as treatment failure despite normalization of PB counts.
Adverse reactions and clinical course. Side effects related to rhGM-CSF were mild (WHO toxicity grade 5 2) and no patient failed to complete a course of treatment because of suspected toxicity. The predominant side effects related to rhGM-CSF were fever greater than 38°C (the increase coincident with the onset of rhGM-CSF) in 13 of 18 pts and mild diarrhea in 10 of 18 pts. Serum albumin decreased in For personal use only. on September 14, 2017 . by guest www.bloodjournal.org From all pts within 1 week (53.8% to 83% of pretreatment values), accompanied by peripheral edema and weight gain in 10 of 18 pts. Hypoalbuminemia persisted as long as rhGM-CSF was administered and then resolved spontaneously. Decreased levels of albumin were associated with low serum pseudocholinesterase levels and a prolonged prothrombin time. The follow-up of these laboratory parameters suggests an rhGM-CSF-mediated effect (Fig 6) . These phenomena were not observed in the historical controls.
Transient serum creatinine elevation up to 256.4 pmol/L (2.9 mg/100 mL) was observed in pt 2, and disappeared after dose reduction of rhGM-CSF (half dosage beyond day 6). In five other pts (4,7,13,14, and 18) 39 In a phase-1/11 study we now used rhGM-CSF in de novo AML pts in combination with standard induction chemotherapy. Our study demonstrates that rhGM-CSF can safely be administered in combination with standard induction chemotherapy in AML pts to recruit leukemic blast cells and to shorten the time of chemotherapy-induced aplasia. In vitro studies have shown that rhGM-CSF promotes growth and survival of normal as well as malignant hematopoietic cells." The potential hazards of in vivo stimulation of leukemia cell growth by rhGM-CSF have prohibited its clinical use in AML pts so far. In this study, rhGM-CSF administered before cytotoxic chemotherapy (in 14 pts) induced a substantial increase in WBC counts caused by elevation of both AML blasts and neutrophils, whereas no apparent growth-promoting effect of GM-CSF on AML blast cells was observed during or after chemotherapy. Elevation of PB blast cell counts during prephase most likely was the result of a direct effect of GM-CSF on malignant AML blasts. This effect of GM-CSF was associated with proliferation of leukemic cells and probably also with redistribution of cells from the BM into the blood stream.
In vivo recruitment of AML blast cells from Go-phase into the chemotherapy-sensitive GI-and S-phases upon stimulation with rhGM-CSF could be demonstrated in all pts tested. In one pt (PB cells) a decrease in Go-cells and an increase in GI-and S-phase cells was assessed by three independent double-labeling techniques (DNNRNA-, D N M r d U -, and DNA/Ki67 analyses). The in vivo increase in S-phase positive blast cells was observed in BM as well as PB specimens. Together, these data provide evidence that rhGM-CSF is capable of recruiting quescient leukemic AML cells in vivo to enter the chemotherapysensitive phases of the cell cycle. In vitro studies have shown that the increase in S-phase induced by GM-CSF is associated with an increased cell kill.35.39 In our study, complete aplasia was observed in all but one pt on day 14 and no delay in chemotherapy-induced blast cell kill (ie, decrease in PB leukocytes during chemotherapy) was seen. We also observed a high rate of CR (83%) with no signs of GM-CSF-induced leukemia cell regrowth. Whether a longer survival time will be obtained in pts using our new protocol remains to be evaluated in ongoing randomized trials.
Recent studies have shown that rhGM-CSF shortens the chemotherapy-induced phase of aplasia in tumor pt~.'~.'' In this study, the duration of chemotherapy-induced neutropenia was significantly shortened in GM-CSF-treated pts (achieving CR after one cycle) compared with historical controls (identical chemotherapy, CR after one cycle) (P < .05). Similar data on the effect of GM-CSF on myeloid recovery have previously been reported in relapsed For personal use only. on September 14, 2017. by guest www.bloodjournal.org From AML p t s ? '~~~ Despite early recovery of neutrophils, severe infections occured. Therefore, a possible influence of GM-CSF-induced accelaration of neutrophil recovery on the incidence and/or severity of infections also remains to be determined in forthcoming trials. Recovery of platelets and restitution of erythropoiesis was not accelerated by administration of GM-CSF compared with historical controls.
Clinical side effects related to rhGM-CSF were mild and tolerable. Fever, mild diarrhea, and peripheral edema were the most dominant complaints. Impaired kidney function occured in three pts receiving rhGM-CSF. However, the increase in creatinine observed in these pts could not definitely be linked to administration of GM-CSF because other nephrotoxic drugs were given simultaneously. The rapid onset of hypoalbuminemia (observed in all pts) accompanied by peripheral edema and weight gain was probably the result of endothelial cell damage and/or because of impaired liver cell function. The underlying mechanisms for such cellular dysfunctions are at present not known. We believe that in addition to a direct effect of GM-CSF on such cells, a preexisting cellular dysfunction caused by the presence of leukemic cells and/or their products could have been a cofactor for GM-CSF-induced side effects. The above mentioned leukemia cell products may for example represent cytokines such as interleukin-6 (IL-6)54-56 because in preliminary investigations we were able to detect increased serum IL-6 levels in pts treated with GM-CSF compared with pretreatment values (data not shown).
We conclude that rhGM-CSF is a potentially useful agent in the treatment of AML in combination with standard induction chemotherapy. Further studies are necessary to evaluate the long-term effects of this new therapeutic concept in AML.
